HOME >> BIOLOGY >> NEWS
Weill Cornell pharmacologist receives prestigious NIH MERIT Award

$2.5 million grant supports research into potential pharmaceutical targets for treating vascular complications of diabetes

NEW YORK (May 21, 2007) -- A leading authority and pioneer in the pharmacology of the signaling molecule nitric oxide (NO), Weill Cornell Medical College scientist Dr. Steven S. Gross has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to receive a 2007 National Institutes of Health (NIH) Method to Extend Research in Time (MERIT) Award, representing the fourth year the College has been selected for the prestigious honor.

This year's $2.5 million five-year research grant will provide long-term support for research aimed at furthering understanding of the NO-related trigger for vascular complications of diabetes and developing novel pharmaceutical approaches for ameliorating the condition.

Dr. Gross is professor of pharmacology, director of the mass spectrometry core facility and principal investigator on an NIH grant that supports the training of Ph.D. candidates in the Graduate School Program in Pharmacology at Weill Cornell Medical College.

"We are extremely grateful for the NIH's continued support for our translational research efforts," says Dr. Antonio M. Gotto Jr., the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College. "Dr. Gross is highly deserving of this honor. His research has uncovered a wealth of information about the important role of nitric oxide in the body. This work, which has laid the groundwork for treatments of numerous disease conditions that have been attributed to nitric oxide excess or insufficiency, is currently focused on new approaches for one of the most painful complications of diabetes."

Beginning in the late 1980s, Dr. Gross and colleagues made several key discoveries about nitric oxide. Working with Dr. Roberto Levi and colleagues at Weill Cornell, Dr. Gross was a member of the first group to administer a selective inh
'"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
21-May-2007


Page: 1 2 3 4

Related biology news :

1. Weill Cornell team identifies potential new cancer drug target
2. Stem cell research at Weill Cornell, The Rockefeller University, and Sloan-Kettering
3. Weill Cornell team develops fast-acting anthrax vaccine
4. Cornell scientists link E. coli bacteria to Crohns disease
5. Methodist, University of Houston, Cornell combine biomedical imaging expertise
6. Cornell lab confirms deadly fish virus spreading to new species
7. NSF awards $3.3 million grant to Cornell to bolster the percentage of women faculty members
8. Cornell researchers find serious fish virus in Northeast for first time
9. Cornell finds natural selection in humans
10. Northeast Sun Grant Institute at Cornell spurs green revolution
11. Cornell graduate student named 2005 AIBS Emerging Public Policy Leader

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2020)... , ... March 13, 2020 , ... ... with Vivorte Inc. to be the exclusive distributor of the Louisville-based company’s orthobiologics ... and medical education expertise to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) and ...
(Date:3/11/2020)... ... March 11, 2020 , ... ... sensing, today announced smart human body temperature infrared touch-free monitoring product family, a ... meter WxS x800-IRTM, supporting flexible wireless uplink for cloud connectivity such as NB-IoT, ...
(Date:3/9/2020)... DALLAS (PRWEB) , ... March ... ... by enterprises witnessed a steep growth rate of 64% last year, as ... to new research from Everest Group. Unfortunately, only 13% of all transformation ...
Breaking Biology News(10 mins):
(Date:3/10/2020)... ... March 10, 2020 , ... Ortho Clinical Diagnostics, a global leader of in ... ORTHOTM Sera, ID-MTS, a suite of extended antigen in a gel testing format used ... ORTHO VISION® and ORTHO VISION® Max in the United States and Canada. The clearances ...
(Date:3/3/2020)... ... March 03, 2020 , ... ... biotech and medical device industries, was recognized by INC. 5,000 on an annual ... lists to note industry leaders greatly impacting their spheres of influence and experiencing ...
(Date:2/21/2020)... ... 2020 , ... In a free session on Tuesday, March 10, ... Lisa Dilworth, BS, MS, Vice President Rare, Orphan and Pediatric Diseases, and Rachael Young, ... to support patients, sites and sponsors. , When planning a rare disease clinical trial, ...
(Date:2/19/2020)... ... February 18, 2020 , ... Shoreline Biome, a ... strain level, recently unveiled a novel DNA isolation product. , Shoreline Rapid Prep ... high molecular weight (HMW) single-stranded DNA (ssDNA) in excess of 40 kB from ...
Breaking Biology Technology:
Cached News: